On Track for September PDUFA Target Action Date on NDA for Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple Myeloma (MM)  Rapidly Advancing U.S. Commercial Activities in Support of Potential September Launch  Announced Publication in Nature Medicine of

Management to Hold Conference Call at 10:00 a.m. EDT TEL AVIV, Israel , May 17, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today that it will release its unaudited financial results for the quarter

TEL AVIV, Israel , April 25, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained

- GENESIS trial achieved statistical significance (p

- Announced FDA Acceptance of APHEXDA® (motixafortide) New Drug Application (NDA) in Stem Cell Mobilization with Prescription Drug User Fee Act (PDUFA) Target Action Date of September 9, 2023 - - Named Tami Rachmilewitz, M.D., as new Chief Medical Officer and Completed Formation of U.S.

Management to Hold Conference Call at 10:00 am EDT TEL AVIV, Israel , March 15, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today that it will release its audited financial results for the year

- Clinical trial part of long-term growth strategy for motixafortide across multiple potential therapeutic areas - TEL AVIV, Israel , March 6, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced a

Experienced Drug Developer Brings Over 15 Years of Clinical Development Industry Knowledge across Multiple Therapeutic Areas and Modalities TEL AVIV, Israel , Jan. 4, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on

Study Met Primary Endpoint for Safety and Tolerability First-in-Human, Single-Agent Study Demonstrated Immune Activity Across Multiple Biomarkers Company to Seek Publication of Complete Data Analysis in 2023  TEL AVIV, Israel , Dec. 20, 2022 /PRNewswire/ -- BioLineRx Ltd.

TEL AVIV, Israel , Nov. 28, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that management will participate in the 12 th Annual LifeSci Partners Corporate Access Event, taking place January 9-11,

- Announced FDA acceptance of APHEXDA® (motixafortide) New Drug Application (NDA) in stem cell mobilization with Prescription Drug User Fee Act (PDUFA) target action date of September 9, 2023 - - Introduced plan to commercialize APHEXDA® independently in the U.S.

Management to hold a conference call at 10:00 a.m.   EST TEL AVIV, Israel , Nov. 10, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended

- PDUFA target action date set for September 9, 2023 - NDA submission based on GENESIS Phase 3 trial data that met all primary and secondary endpoints with a high level of statistical significance - Company advancing preparations for robust commercial launch TEL AVIV, Israel , Nov.

TEL AVIV, Israel , Nov. 4, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq").

Full data from pharmacoeconomic study will be presented demonstrating significant cost benefits from using motixafortide in combination with G-CSF, versus plerixafor with G-CSF, for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation  Phase 1 trial

Company to accelerate availability to patients and maximize value through independent commercialization to well-defined U.S. transplant center community Veteran product launch leader Holly May named President, BioLineRx   USA   Company introduces APHEXDA as Motixafortide's FDA approved trade name

TEL AVIV, Israel , Sept. 19, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a

Funds to be used to support aggressive commercial launch in the US for Motixafortide in stem cell mobilization, if approved TEL AVIV, Israel , Sept. 15, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today

Submission based on overwhelmingly positive top-line results from GENESIS Phase 3 study  Stem cell mobilization for bone marrow transplantation estimated to be > $360 million market in the U.S. ( > $500 million globally), with consistent growth  TEL AVIV, Israel , Sept.

- Submission of New Drug Application to FDA for Motixafortide in stem cell mobilization (SCM) for autologous stem cell transplantation expected within next 4-6 weeks - - Announced appointment of commercial strategy and operations veteran Holly May as U.S.

Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , Aug. 11, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter

- GenFleet to design and execute randomized Phase 2b triple combination trial of Motixafortide in first-line metastatic PDAC patients in China - - BioLineRx to retain global rights to Motixafortide in all indications - -Collaboration based on positive final results from Phase 2a COMBAT/KEYNOTE-202

  - Appointment adds diverse commercial experience in new product planning, commercialization strategies and launch readiness spanning 13 career launches, including specific expertise in hematopoietic stem cell mobilization - TEL AVIV, Israel , June 16, 2022 /PRNewswire/ -- BioLineRx Ltd.

- On track to submit New Drug Application to FDA for Motixafortide in stem cell mobilization (SCM) for autologous stem cell transplantation in mid-2022, consistent with prior guidance - - Progressing critical Motixafortide pre-launch activities while maintaining full optionality on

Management to hold a conference call at 10:00 a.m.   EDT TEL AVIV, Israel , May 5, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter

- Commercial assessment commissioned indicating US stem-cell mobilization opportunity of ~$360m - Successful pre-NDA meeting with FDA; NDA submission anticipated in mid-2022 - Announced highly positive results from additional pharmacoeconomic study indirectly comparing Motixafortide plus G-CSF

Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel , March 10, 2022 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX), (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its audited financial results for the year

- Results demonstrate highly significant cost benefits of using Motixafortide in combination with G-CSF, versus plerixafor with G-CSF, for stem cell mobilization in all multiple myeloma patients undergoing autologous stem cell transplantation - Results reinforce and enhance the economic benefit

- Initial results anticipated in the first half of 2022 TEL AVIV, Israel , Jan. 24, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced that the Company has completed enrollment of the Phase 1/2a study

- NDA submission on track for H1 2022 TEL AVIV, Israel , Jan. 18, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ-CM: BLRX) (TASE: BLRX) a late clinical-stage biopharmaceutical company focused on oncology, today announced that the Company has completed a successful pre-New Drug Application (NDA)

- Presentation highlighted successful GENESIS Phase 3 pivotal trial of Motixafortide plus G-CSF for stem cell mobilization in multiple myeloma patients - - Pre-NDA meeting imminent; NDA submission anticipated in H1 2022 - TEL AVIV, Israel , Dec. 17, 2021 /PRNewswire/ --  BioLineRx Ltd.

SAB will provide insight and guidance on the Company's immuno-oncology activities and is comprised of recognized leaders in the fields of cancer immunology, intra-tumoral injections and clinical development TEL AVIV, Israel , Dec. 15, 2021 /PRNewswire/ -- BioLineRx Ltd.

- Positive results from pharmacoeconomic cost effectiveness study of Motixafortide in stem cell mobilization support its use as standard of care in combination with G-CSF - - Pre-NDA meeting with FDA set for mid-December; NDA submission planned for H1 2022 - - Cash and cash equivalents at September

Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel , Nov. 12, 2021 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter

- Oral presentation highlights successful GENESIS Phase 3 pivotal trial of Motixafortide plus G-CSF for stem cell mobilization in multiple myeloma patients - - Presentations include data showing the addition of Motixafortide to G-CSF rapidly mobilizes large numbers of specific stem cells, which may

- Results demonstrate significant cost benefits of using Motixafortide in combination with G-CSF as standard-of-care mobilization therapy for all multiple myeloma patients undergoing autologous stem cell transplantation - - Results from pre-planned study, on top of highly significant and clinically

- Company actively preparing for an NDA submission for Motixafortide in stem cell mobilization targeted for H1 2022 - - Cash and cash equivalents of $66 million at June 30, 2021 - - Management to hold conference call today, August 18, at 10:00 am EDT - TEL AVIV, Israel , Aug.

Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , Aug. 12, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter

- Phase 3 GENESIS study in stem-cell mobilization (SCM) demonstrated highly statistically significant positive results across all primary and secondary endpoints - - ~90% of patients in treatment arm underwent transplantation following only one dose of Motixafortide and only one apheresis session;

Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , May 20, 2021 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter

- Study met all primary and secondary endpoints with exceptionally high level of statistical significance (p

- Poster includes analysis of results by liver metastases, further strengthening results reported in December 2020 of the COMBAT/KEYNOTE-202 triple combination study of motixafortide in metastatic pancreatic cancer - - Company also on track to report final data from Phase 3 GENESIS trial of

- Phase 3 GENESIS study in stem-cell mobilization (SCM) showed statistically significant positive results for primary endpoint in interim analysis; enrollment ceased early; top-line data expected early Q2 2021 - - Final results from Phase 2a COMBAT/KEYNOTE-202 study of motixafortide in pancreatic

Management to hold conference call at 10:00 a.m. EST TEL AVIV, Israel , Feb. 17, 2021 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its audited financial results for the year ended

TEL AVIV, Israel , Jan. 22, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced the closing of its previously announced underwritten offering of 14,375,000 American Depositary Shares (ADSs) of the

TEL AVIV, Israel , Jan. 20, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on

TEL AVIV, Israel , Jan. 19, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed

- Substantial improvement observed across all study endpoints, including overall survival, progression free survival and overall response rate, in the most challenging PDAC patients - - Company plans to meet with regulatory authorities as it evaluates next development steps - - Company to host Key

- Phase 3 GENESIS study in SCM showed statistically significant positive results for primary endpoint in interim analysis; enrollment halted early; topline data in H1 2021 -   - Interim analysis for Phase 2b BLAST study in consolidation AML did not demonstrate statistically significant effect in

Management to hold a conference call at 10:00 a.m.   EST TEL AVIV, Israel , Nov. 18, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter

- Investigator-initiated study, led by Wolfson Medical Center, to evaluate Motixafortide in up to 25 patients hospitalized with ARDS -   - Results of preliminary analysis expected in H1 2021- TEL AVIV, Israel , Nov. 18, 2020 /PRNewswire/ --  BioLineRx Ltd.

- Enrollment to cease immediately; topline data anticipated in H1 2021- TEL AVIV, Israel , Oct. 30, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a planned interim analysis of

- Investigator-initiated Phase 2 study, led by Columbia University, to evaluate Motixafortide in combination with LIBTAYO® and chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma - TEL AVIV, Israel , Oct. 29, 2020 /PRNewswire/ --  BioLineRx Ltd.

- Interim analysis in GENESIS to be completed in next few months - TEL AVIV, Israel , Aug. 19, 2020 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that a sufficient number of patients (~65% of the

- On track to report three significant data readouts in next few months -   - Completes successful financings, raising gross proceeds of $13.4 million; sufficient to reach multiple important milestones -   - Management to hold conference call today, August 6, at 10:00 am EDT - TEL AVIV, Israel ,

Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , July 31, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter

TEL AVIV, Israel , June 1, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into definitive agreements with several healthcare-focused, institutional and accredited investors for

TEL AVIV, Israel , May 27, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that a paper, entitled 'BL-8040, a CXCR4 Antagonist, in Combination with Pembrolizumab and Chemotherapy for Pancreatic Cancer:

TEL AVIV, Israel , May 26, 2020 /PRNewswire/ --  BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into definitive agreements with several healthcare-focused, institutional and accredited investors

- On track to report progression free survival and overall survival data from triple combination arm of ongoing COMBAT/KEYNOTE-202 Phase 2a trial in mid-2020 - Key data readouts in AML and stem cell mobilization expected by year-end - Management to hold conference call today, May 20, at 10:00 am

Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , May 15, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter

- On track to report progression free survival and overall survival data from triple combination arm of ongoing COMBAT/KEYNOTE-202 Phase 2a trial in mid-2020 - - Management to hold conference call today, March 12, at 10:00 am EDT - TEL AVIV, Israel , March 12, 2020 /PRNewswire/ -- BioLineRx Ltd.

Management to hold conference call at 10:00 a.m. EDT TEL AVIV, Israel , March 6, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its audited financial results for the year ended

TEL AVIV, Israel , Feb. 27, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX), (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent

TEL AVIV , Israel , Jan. 22, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today the completion of patient recruitment in the triple combination arm of its ongoing Phase 2a COMBAT/KEYNOTE-202 study.

TEL AVIV, Israel , Jan. 14, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced that the European Commission (EC) has granted Orphan Drug Designation to its lead oncology candidate, Motixafortide (BL-8040),

TEL AVIV, Israel , Jan. 8, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that management will provide a corporate update at the 2020 Biotech Showcase in San Francisco, California .

- Combination of BL-8040, KEYTRUDA® and chemotherapy demonstrates a 32% overall response rate and a 77% disease control rate out of 22 currently evaluable patients - - Median duration of clinical benefit for all 17 patients with disease control (7 PR and 10 SD patients) is 7.8 months - - Patient

- Combination of BL-8040, KEYTRUDA® and chemotherapy showed high level of disease control, including 4 partial responders and 8 patients with stable disease out of 15 evaluable patients - - Study is ongoing; progression free survival and overall survival not yet reached; survival data expected in

TEL AVIV, Israel , Nov. 26, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that it will host an investor breakfast meeting on Thursday, December 5, 2019 at the Convene Conference Center near Grand

- On track for Phase 2 triple-combination data read-outs in pancreatic cancer by year-end 2019 - - Management to hold conference call today, November 11, at 10:00am EST - TEL AVIV, Israel , Nov. 11, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical

Management to hold conference call at 10:00 a.m. EST TEL AVIV, Israel , Nov. 6, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended

- Results of the Phase 2b trial are being presented by MD Anderson Cancer Center at SITC 2019 - TEL AVIV , Israel , Nov. 5, 2019 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) and (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today results of a Phase 2b

- Results are being presented at SITC 2019 - TEL AVIV , Israel , Nov. 5, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today positive preclinical results further elucidating the mechanism of action of

- Presentations include triple-combination pre-clinical data and dual-combination clinical data for BL-8040 in pancreatic cancer - TEL AVIV , Israel , Oct. 31, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced

- Proffered paper presentation to highlight new clinical data from a Phase 2a study evaluating BL-8040 in combination with pembrolizumab and chemotherapy in metastatic pancreatic cancer - TEL AVIV , Israel , Oct. 29, 2019 /PRNewswire/ --  BioLineRx Ltd.

- Initial results of part 2 of the study expected by year-end 2020 -     TEL AVIV , Israel , Sept. 25, 2019 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) and (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today dosing of the first patient in part 2 of the

AGI-134 was found to be safe and well tolerated with no dose-limiting toxicities observed Dose expansion part of study expected to commence shortly, with initial results expected by year-end 2020 TEL AVIV, Israel , Sept. 3, 2019 /PRNewswire/ -- BioLineRx Ltd.

On track for Phase 2 data read-out in pancreatic cancer by year-end 2019 Management to hold conference call today, August 6, at 10:00 am EDT TEL AVIV, Israel , Aug. 6, 2019 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology,

Management to hold conference call at 10:00 a.m. EDT TEL AVIV, Israel , July 30, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended

TEL AVIV, Israel , June 28, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary

TEL AVIV, Israel , June 13, 2019 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Chief Executive Officer, Philip Serlin , will present a company update at the JMP Securities 2019 Life Sciences

On track for Phase 2 data read-outs in pancreatic cancer and consolidation AML by year-end 2019 Management to hold conference call today, May 14, at 10:00 am EDT TEL AVIV, Israel, May 14, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company

Management to hold a conference call at 10:00 a.m. EDT Tel Aviv, Israel, May 7, 2019 --- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended March 31, 2019 on

- Phase 1/2a study ongoing in the UK and Israel, with sites in the US expected to join by H1 2020 - - Initial safety results expected in H2 2019; initial efficacy results expected by year-end 2020 - TEL AVIV, Israel, May 7, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a

BL-8040 and AGI-134 oncology programs progressing, with multiple data read-outs expected in the next 12 months Management to hold conference call today, March 28, at 10:00 am EDT TEL AVIV, Israel, March 28, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage

Results presented as oral presentation at 45th Annual Meeting of European Society for Blood and Marrow Transplantation TEL AVIV, Israel, March 27, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that

Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel, March 21, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its audited annual financial results for the year

TEL AVIV, Israel, March 14, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Chief Executive Officer, Philip Serlin, will present a company update at the 29th Annual Oppenheimer Healthcare

TEL AVIV ,   Israel , Feb. 7, 2019 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has closed its previously announced underwritten public offering of 28,000,000 American Depositary Shares

TEL AVIV, Israel , Feb. 5, 2019 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has priced an underwritten public offering of 28,000,000 American Depositary Shares ("ADSs"), each representing

TEL AVIV, Israel , Feb. 4, 2019 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has commenced an underwritten public offering of American Depositary Shares ("ADSs"), each representing one of

TEL AVIV, Israel , Feb. 4, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that the U.S. Food and Drug Administration ( FDA ) has granted Orphan Drug Designation to its lead oncology candidate, BL-8040,

TEL AVIV, Israel , January 2, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that management will provide a corporate update at the 2019 Biotech Showcase in San Francisco, California .

Results of triple combination arm of BL-8040, KEYTRUDA® and chemotherapy expected in H2 2019 TEL AVIV, Israel , Dec. 11, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the initiation of

TEL AVIV, Israel , December 6, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will host an investor breakfast meeting on Tuesday, December 11, 2018 at the Convene Conference

- Designation provides eligibility for 12 years of market exclusivity that complements robust IP estate - - Phase 1/2a study ongoing with topline data expected by year-end 2020 - TEL AVIV, Israel , Nov. 20, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage

Management to hold conference call at 10:00 am EST TEL AVIV, Israel , Nov. 8, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the third quarter ended September 30,

Management to hold conference call at 10:00 a.m. EST TEL AVIV, Israel , November 1, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will release its unaudited financial results for the

Results presented today demonstrate that BL-8040 significantly improves T-cell infiltration into the tumor and reduces immunosuppression in the tumor microenvironment TEL AVIV, Israel , October 20, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) (TASE: BLRX.TA), a clinical-stage

BL-8040 in combination with KEYTRUDA® (pembrolizumab) demonstrated encouraging disease control and overall survival in patients with metastatic pancreatic cancer Encouraging results support further development of combination and expansion of collaboration Triple combination expansion cohort

Transaction increases BioLineRx's stake by 20%, to 80%, ahead of numerous potential value-creating milestones Top-line results from ongoing Phase 2a pancreatic cancer study in combination with KEYTRUDA® expected this quarter Management to hold conference call today, October 3, at 10:00 am EDT TEL

TEL AVIV, Israel , August 30, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that its Chief Executive Officer, Philip Serlin , will present a company update at the 20th Annual Rodman &

TEL AVIV, Israel , Aug. 13, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the second quarter ended June 30, 2018 .

Data from first lead-in patient cohort prompts Data Monitoring Committee to recommend early continuation to randomized placebo-controlled part 2 of trial TEL AVIV, Israel , August 7, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused

Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , Aug. 6, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will release its unaudited financial results for the

TEL AVIV , Israel , August 1, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it has initiated a Phase 1/2a clinical study for AGI-134, a novel compound that evokes a direct

30-50 patients in additional arm will be investigated under the collaboration Results from combination of BL-8040 and KEYTRUDA® (pembrolizumab) in COMBAT/KEYNOTE-202 study will be reported in H2 2018 as planned TEL AVIV, Israel , July 30, 2018 /PRNewswire/ -- BioLineRx Ltd.

Data presented at EHA shows significantly improved overall survival compared to historical data Potential biomarker identified for future patient selection, based on statistically significant correlation between responders and levels of AML blast mobilization to peripheral blood TEL AVIV, Israel ,

TEL AVIV, Israel , June 13, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief Executive Officer, Philip Serlin , will participate in a panel discussion at JMP Securities 2018

TEL AVIV, Israel , May 22, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the first quarter ended March 31, 2018 .

BL-8040 in combination with Cytarabine showed significantly improved overall survival compared to historical data TEL AVIV, Israel , May 17, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced

- BL-8040 was safe and well tolerated, and all transplanted recipients were successfully engrafted - - Full top-line results will be presented at the 23rd EHA Congress - TEL AVIV, Israel , May 17, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical

Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , May 16, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX)( TASE: BLRX)( BLRX) , a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will release its unaudited financial results

Patent valid through March 2034, with up to five years' patent term extension TEL AVIV, Israel , May 16, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX)( BLRX) , a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that the European Patent

TEL AVIV, Israel , March 26, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a

TEL AVIV, Israel , March 14, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief Executive Officer, Philip Serlin , will present a company update at the 28 th Annual

TEL AVIV, Israel , March 6, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the year ended December 31, 2017 . Highlights and achievements in 2017 and to date: Continued

Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel, Feb. 27, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will release its audited annual financial results for

TEL AVIV, Israel , Feb. 6, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief Executive Officer, Philip Serlin , will present a company update at the 2018 BIO CEO & Investor

TEL AVIV , Israel , January 23, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) (TASE: BLRX.TA) a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the publication of data showing that BL-8040, its lead oncology platform, augments the

- AGI-134 on track to commence Phase 1/2a clinical study in H1 2018 - TEL AVIV, Israel , January 23, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) (TASE: BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that AGI-134, an

- BL-8040 monotherapy resulted in increased infiltration of T cells into tumor - - Data to be presented at the upcoming ASCO-GI conference; topline clinical results expected by H2 2018 as planned - TEL AVIV , Israel , Jan. 17, 2018 /PRNewswire/ --  BioLineRx Ltd.

Study will assess mobilization of hematopoietic stem cells by BL-8040 compared to placebo, on top of G-CSF, for autologous transplantation in multiple myeloma patients TEL AVIV, Israel , December 21, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical

TEL AVIV, Israel , Dec. 5, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today hosts its investor breakfast meeting at the Convene Conference Center near Grand Central in New York, NY .

BL-8040 in combination with high-dose Ara-C significantly improved overall survival compared to historical data TEL AVIV, Israel , December 4, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced

TEL AVIV, Israel , Nov. 21, 2017 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the third quarter ended September 30, 2017 . Highlights and achievements during the third

Enrollment to COMBAT study has been completed; full topline results expected in H2 2018 as planned TEL AVIV, Israel , November 20, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that an

TEL AVIV, Israel , November 16, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will host an investor breakfast meeting on Tuesday, December 5, 2017 at the Convene Conference

Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel , November 9, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its unaudited financial results

- Preclinical data demonstrate that BL-8040 mobilizes a significant number of these HSCs compared to G-CSF, thus potentially improving graft quality - TEL AVIV, Israel , November 2, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company focused on

Combination trial of BL-8040 and atezolizumab is part of initiative for the development of novel cancer immunotherapy combinations TEL AVIV, Israel , October 18, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and

The BATTLE trial will investigate the combination of BL-8040 and atezolizumab under cancer immunotherapy collaboration TEL AVIV, Israel , September 26, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology,

TEL AVIV, Israel , September 7, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that its Chief Executive Officer, Philip Serlin , and its Chief Business Officer, David Malek , will present

- GENESIS is a Phase 3 trial for the mobilization of hematopoietic stem cells for autologous transplantation in patients with multiple myeloma - - Initiation of study expected by end of 2017 - TEL AVIV , Israel , Aug 21, 2017 /PRNewswire/ -- BioLineRx Ltd.

TEL AVIV, Israel , Aug. 8, 2017 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the second quarter ended June 30, 2017 . Highlights and achievements during the second quarter

Management to hold conference call at 10:00 a.m. EDT TEL AVIV, Israel , August 2, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its unaudited financial results for

TEL AVIV, Israel , July 26, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that BVF Partners L.P. (BVF), its largest shareholder, has entered into a definitive agreement to make an

Combination trial of BL-8040 and atezolizumab are part of initiative for the development of novel cancer immunotherapy combinations TEL AVIV, Israel , July 10, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology,

TEL AVIV, Israel , June 1, 2017 /PRNewswire/ -- - Genentech has submitted all three solid tumor trials planned under it s cancer immunotherapy collaboration with BioLineRx -   - Studies will investigate the combination in pancreatic cancer,   gastric cancer and non-small cell lung cancer (NSCLC) -

TEL AVIV, Israel , May 25, 2017 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the first quarter ended March 31, 2017 . Highlights and achievements during the first quarter

Phase 1b trial under cancer immunotherapy collaboration with Genentech TEL AVIV, Israel , May 22, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the filing of regulatory submissions

Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , May 16, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its unaudited financial results for the

TEL AVIV, Israel , May 3, 2017 /PRNewswire/ -- - Initiation of Phase 3 registrational study expected in second half of this year  - Study to focus on stem cell mobilization for autologous transplantation in multiple myeloma patients BioLineRx Ltd. (NASDAQ/TASE: BLRX, BLRX.TA), a clinical-stage

TEL AVIV, Israel , April 5, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical stage biopharmaceutical development company focused on oncology and immunology, today announced that it has closed its previously announced underwritten public offering of approximately 33.8 million

TEL AVIV, Israel , March 31, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical stage biopharmaceutical development company focused on oncology and immunology, today announced that it has priced an underwritten public offering of approximately 29.4 million American Depositary

TEL AVIV, Israel , March 30, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical stage biopharmaceutical development company focused on oncology and immunology, today announced that it has commenced an underwritten public offering of American Depositary Shares ("ADSs"), each

TEL AVIV, Israel , March 27, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that AGI-134, an immunotherapy for the treatment of multiple cancers, obtained through its recently announced

TEL AVIV, Israel , March 23, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX,  TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the year ended December 31, 2016 . Highlights and achievements in 2016 and to date:

Agalimmune's Lead Asset, AGI-134, Provides a Unique Approach for Eliciting Patient-specific, Anti-tumor Immune Responses in Multiple Cancer Types TEL AVIV, Israel , March 23, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and

TEL AVIV, Israel , March 20, 2017 /PRNewswire/ -- - Results to date confirm that s ingle injection of BL-8040   mobilize s sufficient amounts of cells required for   allogeneic transplantation without need for G-CSF -   - Top -l ine results expected by end of 201 7 -   BioLineRx Ltd.

Management to hold a conference call at 9:00 a.m. EDT TEL AVIV, Israel , March 16, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its audited annual financial results for

TEL AVIV, Israel , February 7, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief Executive Officer, Philip Serlin , and its Chief Business Officer, David Malek , will present a

Study is part of strategic research collaboration between MSD and MD Anderson Cancer Center aimed to evaluate KEYTRUDA in selected GI tumors using various combinations TEL AVIV, Israel , January 17, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical

TEL AVIV, Israel , January 4, 2017 /PRNewswire/ -- BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Philip Serlin , will be presenting

TEL AVIV, Israel , December 5, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase 2a correlative data, as well as detailed

TEL AVIV, Israel , Nov. 22, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the third quarter ended September

Therapeutic compound is third project in-licensed under strategic collaboration with Novartis for screening and development of novel drug candidates TEL AVIV, Israel , November 21, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to

Management to hold conference call at 10:00 a.m. EST TEL AVIV, Israel , November 15, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it

TEL AVIV, Israel , November 3, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, disclosed today positive Phase 2a correlative data, as well as detailed

TEL AVIV, Israel , October 5, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that data on BL-8040, the Company's leading oncology platform,

Therapeutic compound is second project in-licensed under strategic collaboration with Novartis for screening and development of novel drug candidates TEL AVIV, Israel , September 23, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to

- Presentation includes details of 2017 operating plan and five-year Company vision - TEL AVIV, Israel , September 22, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic

TEL AVIV, Israel , September 20, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE:BLRX) today announced the initiation of a Phase 2a trial investigating BL-8040 in combination with KEYTRUDA ® (pembrolizumab), MSD's anti-PD-1 therapy, in patients with metastatic pancreatic cancer.

TEL AVIV, Israel , September 9, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE : BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will host an investor breakfast meeting on Thursday,

Combination of BL-8040 with Ara-C in difficult-to-treat patient population demonstrated substantial improvement over clinical response rates historically achieved with Ara-C TEL AVIV, Israel , September 8, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced that the successful final

Cancer immunotherapy collaboration with Genentech includes several Phase 1b combination studies for multiple solid tumor indications and AML TEL AVIV, Israel , September 7, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX) today announced that it has entered into a collaboration with

TEL AVIV, Israel , August 29, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Financial and Operating Officer, Philip

JV will promote development and commercialization of Israeli-sourced therapeutic assets for Chinese healthcare market TEL AVIV, Israel , August 25, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and

TEL AVIV, Israel , Aug. 11, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the second quarter ended June 30,

TEL AVIV, Israel , August 11, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Philip A.

- Phase 2 study is part of strategic clinical research collaboration between MSD and MD Anderson Cancer Center aimed at evaluating KEYTRUDA in selected GI tumors using various combinations - TEL AVIV, Israel , August 8, 2016 /PRNewswire/ -- BioLineRx Ltd.

Management to hold conference call at 10:00 a.m. EDT TEL AVIV, Israel , August 4, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will

Novel drug candidate modulates immune system to reduce liver fibrosis in non-alcoholic steatohepatitis TEL AVIV, Israel , August 1, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising

- Study expected to commence during Q3 2016 -   TEL AVIV, Israel , June 28, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the filing of

TEL AVIV , Israel , June 15, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky ,

TEL AVIV, Israel , May 19, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that BL-8040, its lead platform for the treatment of multiple cancer and hematological indications, will be presented at two upcoming scientific conferences.

TEL AVIV, Israel , May 17, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the first quarter ended March 31, 2016 .

TEL AVIV, Israel , May 16, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX ), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a framework collaboration agreement with MaRS

Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , May 10, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX ), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will

- Results identify specific targets in the apoptotic pathway - TEL AVIV, Israel , April 19, 2016 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that detailed results from a study on the underlying mechanism of action of BL-8040, its lead platform for the treatment of multiple

TEL AVIV, Israel , April 4, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that its partner, Omega Pharma, now part of Perrigo , has received CE Mark approval for BL-5010 as a novel OTC treatment for the non-surgical removal of skin lesions.

Data identify a potential biomarker for future selection of BL-8040-responsive AML patients TEL AVIV, Israel , March 29, 2016 /PRNewswire/ -- BioLineRx (NASDAQ/TASE: BLRX) announced today positive top-line results from BL-8040's Phase 2 clinical trial in relapsed or refractory acute myeloid

Partial results expected by end of 2016 TEL AVIV, Israel , March 23, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE:BLRX) announced today the initiation of a Phase 2 trial for BL-8040 as a novel approach for the mobilization and collection of bone marrow stem cells from the peripheral blood

TEL AVIV, Israel , March 10, 2016 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the year ended December 31, 2015 .

TEL AVIV, Israel , March 10, 2016 /PRNewswire/ -- BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its

Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel , March 3, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it

TEL AVIV, Israel , February 1, 2016 /PRNewswire/ -- BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its

BL-7010 receives designation as Class IIb medical device TEL AVIV, Israel , January 25, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it

BioLineRx management to hold conference call this morning at 10:00 am EST to further discuss this immunotherapy collaboration TEL AVIV, Israel , January 12, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX) today announced a collaboration with MSD, known as Merck in the US and Canada , to

TEL AVIV, Israel , January 4, 2016 /PRNewswire/ -- BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its

Study will be conducted in collaboration with Washington University School of Medicine , Division of Hematology and Oncology TEL AVIV, Israel --(BUSINESS WIRE)--Dec. 14, 2015-- BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and

TEL AVIV, Israel --(BUSINESS WIRE)--Dec. 3, 2015-- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported the establishment of a Scientific Advisory Board (SAB) to provide

TEL AVIV, Israel --(BUSINESS WIRE)--Nov. 25, 2015-- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it will host an investor breakfast on Thursday, December 3,

TEL AVIV, Israel --(BUSINESS WIRE)--Nov. 24, 2015-- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D.,

Efficacy and safety study, in collaboration with MD Anderson Cancer Center , will assess BL-8040 as combination treatment with immunosuppressants Interim results of study, in patients with hypoplastic myelodysplastic syndrome (hMDS) and aplastic anemia (AA), expected by end of 2016 TEL AVIV, Israel

TEL AVIV, Israel --(BUSINESS WIRE)--Nov. 16, 2015-- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the third quarter ended September 30,

Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel --(BUSINESS WIRE)--Nov. 9, 2015-- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it

- Data strongly suggest BL-8040 has potent anti-leukemic activity in combination with Ara-C in AML - - Results to be presented at 2015 ASH Annual Meeting - TEL AVIV, Israel --(BUSINESS WIRE)--Nov. 5, 2015-- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to

Study collaboration with MD Anderson Cancer Center will assess BL-8040 as combination treatment with immunosuppressants TEL AVIV, Israel --(BUSINESS WIRE)--Sep. 10, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing

- Product expected to reach the market in 2016 - TEL AVIV, Israel --(BUSINESS WIRE)--Sep. 9, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its

TEL AVIV, Israel --(BUSINESS WIRE)--Sep. 3, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky ,

TEL AVIV, Israel --(BUSINESS WIRE)--Aug. 20, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the second quarter ended June

- Phase 2b study, as consolidation treatment for AML patients responding to standard induction treatment, will enroll up to 194 patients, randomized in 1:1 ratio, at up to 25 sites in Germany - - Study is first of three additional clinical studies for BL-8040 platform expected to commence during

Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel --(BUSINESS WIRE)--Aug. 13, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today

TEL AVIV, Israel --(BUSINESS WIRE)--Jul. 27, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its partner, Bellerophon, reported top-line results

TEL AVIV, Israel --(BUSINESS WIRE)--Jun. 17, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will present positive safety results of its Phase

TEL AVIV, Israel --(BUSINESS WIRE)--Jun. 16, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Financial and Operating Officer, Philip

BL-8040’s rapid stem-cell mobilization supports stand-alone one-day treatment for stem-cell collection Graft derived from BL-8040 treatment shows unique cell composition TEL AVIV, Israel --(BUSINESS WIRE)--Jun. 15, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical

TEL AVIV, Israel --(BUSINESS WIRE)--Jun. 3, 2015-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that research underlying BL-9020, for the treatment of Type 1

- Previously reported results published in British Journal of Dermatology - JERUSALEM --(BUSINESS WIRE)--Jun. 1, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates,

JERUSALEM --(BUSINESS WIRE)--May 27, 2015-- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE: BLRX ), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that positive safety and efficacy Phase 1 clinical data of its

JERUSALEM --(BUSINESS WIRE)--May 18, 2015-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the first quarter ended March 31, 2015 .

Management to hold a conference call at 10:00 a.m. EDT JERUSALEM --(BUSINESS WIRE)--May 11, 2015-- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE: BLRX ), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it

BL-8040 remains safe and well tolerated at highest dose; continues to induce robust mobilization and leukemia cell death Top-line results expected Q4 2015 JERUSALEM --(BUSINESS WIRE)--May 4, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to

- BL-8040 Phase 1 study met all safety and efficacy endpoints - - High stem-cell yield supports novel single-day collection procedure - JERUSALEM --(BUSINESS WIRE)--Mar. 25, 2015-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying,

JERUSALEM --(BUSINESS WIRE)--Mar. 23, 2015-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the year ended December 31, 2014 .

- Management to hold conference call at 10:00 a.m. EDT - JERUSALEM --(BUSINESS WIRE)--Mar. 17, 2015-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that

JERUSALEM --(BUSINESS WIRE)--Mar. 11, 2015-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has closed its previously announced underwritten public

- Results of experiments with BL-9020, a new antibody treatment, published in PLoS One - JERUSALEM --(BUSINESS WIRE)--Mar. 11, 2015-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic

JERUSALEM --(BUSINESS WIRE)--Mar. 6, 2015-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its

JERUSALEM --(BUSINESS WIRE)--Mar. 6, 2015-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has priced an underwritten public offering of 12,500,000

JERUSALEM , March 5, 2015 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has commenced an underwritten public offering of American

- BL-8040 Phase 2b study, as consolidation treatment for AML patients responding to standard induction treatment, is expected to commence shortly after receipt of regulatory approval, anticipated in next few months - JERUSALEM --(BUSINESS WIRE)--Mar. 2, 2015-- BioLineRx Ltd.

JERUSALEM --(BUSINESS WIRE)--Feb. 3, 2015-- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its

- PRESERVATION I trial completion anticipated in mid-2015 - JERUSALEM --(BUSINESS WIRE)--Jan. 14, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that

- Results of Phase 1 trial for BL-8040 expected in Q1 2015 - - Multiple additional clinical milestones for BL-8040 anticipated in 2015 - JERUSALEM --(BUSINESS WIRE)--Jan. 6, 2015-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying,

JERUSALEM --(BUSINESS WIRE)--Jan. 6, 2015-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its

- Omega Pharma to develop and commercialize novel skin treatment for OTC use in Europe and additional selected countries - - First product expected to reach the market in 2016 - JERUSALEM --(BUSINESS WIRE)--Dec. 23, 2014-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage

- Global pharmaceutical company makes initial $10 million equity investment in BioLineRx - - BioLineRx to host conference call today, December, 16 at 10:00 a.m. EST - JERUSALEM --(BUSINESS WIRE)--Dec. 16, 2014-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company

- Clinical trials in three additional indications for BL-8040 to be initiated in 2015 - - Development strategy presented today at BioLineRx investor meeting in New York - NEW YORK --(BUSINESS WIRE)--Dec. 12, 2014-- During an investor and analyst meeting hosted today in New York , BioLineRx Ltd.

- Data show six-fold increase in mobilization of AML cells from bone marrow; Treatment with BL-8040 as single agent led to 70% decrease in AML cells in bone marrow and 3.5-fold increase in AML cell apoptosis - JERUSALEM --(BUSINESS WIRE)--Dec. 8, 2014-- BioLineRx Ltd.

JERUSALEM--(BUSINESS WIRE)--Nov. 10, 2014-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the third quarter ended September 30, 2014 .

- Optimal safe dose of BL-7010 determined for upcoming randomized efficacy study - - Lack of systemic exposure of BL-7010 likely supports medical-device classification in Europe - JERUSALEM --(BUSINESS WIRE)--Nov. 5, 2014-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage

- Management to hold conference call at 10:00 a.m. EST - JERUSALEM --(BUSINESS WIRE)--Nov. 3, 2014-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it

- Amendment will include testing of higher doses, resulting in increase of total study population to up to 70 patients - - Changes unanimously recommended by Clinical Advisory Board - JERUSALEM --(BUSINESS WIRE)--Nov. 3, 2014-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage

- Results of first-in-man study published in Circulation: Cardiovascular Interventions - - BCM (BL-1040) is currently undergoing PRESERVATION I, a CE Mark registration trial conducted by Bellerophon, with study completion anticipated in mid-2015 - JERUSALEM --(BUSINESS WIRE)--Oct.

- Results in this additional indication for BL-8040 presented at Society of Hematologic Oncology (SOHO) Annual Meeting - - BL-8040 also undergoing Phase 2 study in AML, with final results expected in early 2015; and Phase 1 study in stem cell mobilization, with results expected by year-end 2014 or

Results from Phase 1 trial expected by end of 2014 or early 2015; BL-8040 also in midst of Phase 2 trial for AML, with results expected in early 2015 JERUSALEM --(BUSINESS WIRE)--Sep. 3, 2014-- BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to

JERUSALEM --(BUSINESS WIRE)--Sep. 2, 2014-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and

- BL-7010 for treatment of celiac disease is currently in final stages of Phase 1/2 safety study; efficacy study expected to commence in early 2015 - JERUSALEM --(BUSINESS WIRE)--Aug. 21, 2014-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to

JERUSALEM --(BUSINESS WIRE)--Aug. 6, 2014-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the second quarter ended June 30, 2014 .

Management to hold a conference call at 10:00 a.m. EDT JERUSALEM --(BUSINESS WIRE)--Jul. 30, 2014-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it

BL-7010 well tolerated in both single- and repeated-dose administrations Supports classification as medical device in Europe due to lack of systemic absorption Company to investigate lower doses of BL-7010 prior to commencing efficacy study expected in early 2015 JERUSALEM --(BUSINESS WIRE)--Jul.

BL-1110 was shown in preclinical studies to enhance analgesic effect of morphine while reducing negative side effects BL-1110 may also be developed for scleroderma JERUSALEM --(BUSINESS WIRE)--Jun. 23, 2014-- BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a clinical-stage biopharmaceutical company

Phase 1 trial of BL-8040 expected to begin in Q3 2014; results expected in late 2014 or early 2015 BL-8040 also in Phase 2 for AML; results expected in early 2015 JERUSALEM --(BUSINESS WIRE)--Jun. 16, 2014-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company

Results of ongoing Phase 1/2 trial for BL-7010 expected in next few weeks JERUSALEM --(BUSINESS WIRE)--Jun. 11, 2014-- BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates,

JERUSALEM --(BUSINESS WIRE)--May 30, 2014-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a purchase agreement for the sale, from time to

Company Poised to Execute on Multiple Clinical Milestones JERUSALEM --(BUSINESS WIRE)--May 20, 2014-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its

Management to hold a conference call at 10:00 a.m. EDT JERUSALEM --(BUSINESS WIRE)--May 15, 2014-- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE: BLRX ), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it

Phase 1/2 study will assess effect of BL-8040 in combination with standard therapy JERUSALEM --(BUSINESS WIRE)--Apr. 10, 2014-- BioLineRx (NASDAQ: BLRX)(TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates,

JERUSALEM --(BUSINESS WIRE)--Mar. 17, 2014-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the year ended December 31, 2013 .

- BL-8040 currently undergoing Phase 2 trial for acute myeloid leukemia (AML), and expected to commence Phase 1 trial in stem cell mobilization in Q2 2014 - - Top-line results from both trials expected in next 9-12 months - JERUSALEM --(BUSINESS WIRE)--Mar. 14, 2014-- BioLineRx Ltd.

- Management to hold conference call at 10:00 a.m. EDT - JERUSALEM --(BUSINESS WIRE)--Mar. 11, 2014-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that

Single administration of BL-7010 was safe and well tolerated at all doses tested BL-7010 now advancing to repeated administration part of study; results expected mid 2014 JERUSALEM --(BUSINESS WIRE)--Mar. 10, 2014-- BioLineRx (NASDAQ: BLRX)(TASE: BLRX), a clinical-stage biopharmaceutical company

JERUSALEM--(BUSINESS WIRE)--Mar. 7, 2014-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has closed its previously announced underwritten public

JERUSALEM--(BUSINESS WIRE)--Mar. 5, 2014-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its

Jerusalem, March 4, 2014 - BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has priced an underwritten public offering of 8,400,000 American Depositary

JERUSALEM, March 3, 2014 /PRNewswire/ --  BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has commenced an underwritten public offering of its American

JERUSALEM , Feb. 24, 2014 /PRNewswire/ --  BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the appointment of Sandra Panem , Ph.D., to its Board of Directors.

- BL-8040 study published in Molecular Cancer Therapeutics - - BL-8040 currently undergoing Phase 2 trial for acute myeloid leukemia (AML), and expected to commence Phase 1 trial in stem cell mobilization in Q2 2014; top-line results from both trials expected in Q4 2014 - JERUSALEM , Feb.

JERUSALEM , Feb. 3, 2014 /PRNewswire/ --  BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its

- BL-8040 previously received Orphan Drug Designation for treatment of Acute Myeloid Leukemia - - BL-8040 expected to commence Phase 1 trial in stem cell mobilization in Q2 2014; top-line results expected in H2 2014 - JERUSALEM , Jan. 23, 2014 /PRNewswire/ --  BioLineRx (NASDAQ: BLRX; TASE: BLRX),

- CE Mark registration trial for BL-5010P expected to begin H1 2014; results expected H2 2014 - JERUSALEM , Jan. 21, 2014 /PRNewswire/ --  BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic

Phase 1 Trial of BL-8040 expected to begin in Q2 2014; top-line results expected in H2 2014 BL-8040 is also in Phase 2 for AML; top-line results expected in H2 2014 JERUSALEM , Jan. 13, 2014 /PRNewswire/ --  BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated

- JHL Biotech to develop and commercialize BL-9020 in China and additional Southeast Asia countries - JERUSALEM and HSINCHU, Taiwan , Jan. 8, 2014 /PRNewswire/ --  BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing

JERUSALEM , Jan. 7, 2014 /PRNewswire/ --  BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its

- Results of Phase 1/2 trial for BL-7010 expected in mid-2014 - JERUSALEM , Dec. 18, 2013 /PRNewswire/ --  BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today

- Initial results for BL-8040 show substantial mobilization of cancer cells and signs of robust cancer cell death (apoptosis) - JERUSALEM , Dec. 16, 2013 /PRNewswire/ --  BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and

BL-8040 is currently in midst of Phase 2 study in AML patients, with partial results expected this month and final results expected in H2 2014 - JERUSALEM , Dec. 10, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that positive

- New results show BL-7040 to reduce pro-inflammatory cytokine levels and improve colon histology in IBD patients BL-7040 was previously shown to be safe and effective in Phase 2a trial completed in Q2 2013 - (Logo:   http://photos.prnewswire.com/prnh/20130730/630769 ) Jerusalem, November 26, 2013

- Results published in Clinical Cancer Research - - Additional clinical trial in stem cell mobilization expected to commence in H1 2014 - JERUSALEM , Nov. 19, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today the publication of

JERUSALEM, Nov. 13, 2013 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, today reported its results for the third quarter ending September 30, 2013 . (Logo: http://photos.prnewswire.com/prnh/20130730/630769 ) Kinneret Savitsky , Ph.D., Chief

Management to hold conference call at 10:00 a.m. EST - JERUSALEM , Nov. 6, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it will release its unaudited financial results for the quarter ended September 30, 2013 on Wednesday,

JERUSALEM , Nov. 5, 2013 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced that it will host an Analyst & Investor Day on Thursday, November 21, 2013 in New York City beginning at 8:15 am EST .

- Study expected to begin by end of 2013 - - Results expected in mid-2014 - JERUSALEM , Nov. 4, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has received regulatory approval from the Finnish National Supervisory

Preclinical data show that BL-9020 prevents formation of Type 1 diabetes JERUSALEM , Oct. 23, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has signed a worldwide, exclusive license agreement with Yissum Research

JERUSALEM , Oct. 7, 2013 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application claiming the composition of

- Study expected to begin in Q4 2013 - - Results expected in mid-2014 - JERUSALEM , Sept. 24, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has filed the necessary regulatory submissions to commence a Phase 1/2 trial for

- Patent valid until at least 2031 - JERUSALEM , Sept. 17, 2013 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for BL-8020, an

JERUSALEM , Sept. 9, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that the U.S. Food & Drug Administration (FDA) has granted an Orphan Drug Designation to BL-8040 as a therapeutic for the treatment of acute myeloid leukemia

JERUSALEM , Sept. 3, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its Chief Financial and Operating Officer, Philip Serlin , will be presenting at the 15 th

JERUSALEM , Sept. 3, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that an Issue Notification has been received from the United States Patent and Trademark Office (USPTO) for US Patent  No.

JERUSALEM , Aug. 28, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its abstract entitled "BL-7010: Non-Absorbable Polymeric Sequestering Agent for Celiac Disease" was accepted for an oral presentation at the 15th

JERUSALEM , Aug. 27, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its Chief Financial and Operating Officer, Philip Serlin , will be presenting at the 2013 Stifel

JERUSALEM , Aug. 19, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today the appointment of B. J. Bormann , Ph.D., to its Board of Directors. (Logo: http://photos.prnewswire.com/prnh/20130730/630769 ) Dr.

JERUSALEM – August 6, 2013 - BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, today reported its results for the quarter ended June 30, 2013. Recent Highlights: BL-1040 (ventricular remodeling) – The PRESERVATION I clinical trial, a CE-Mark registration trial, is

- Results published in the British Journal of Hematology - - BL-8040, currently in Phase 2 study for AML, continues to show promising results in other hematological indications -   Jerusalem, August 5, 2013 - BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced

Management to hold a conference call at 10:00 a.m. EDT JERUSALEM --(BUSINESS WIRE)--Jul. 30, 2013-- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE: BLRX ), a biopharmaceutical development company, announced today that it will release its unaudited financial results for the quarter ended June 30, 2013 on

- Study expected to begin in Q4 2013 - - Results expected in mid-2014 - JERUSALEM --(BUSINESS WIRE)--Jul. 29, 2013-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has filed the necessary regulatory submissions to commence a pivotal, CE-Mark

JERUSALEM --(BUSINESS WIRE)--Jul. 2, 2013-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its Chief Financial and Operating Officer, Philip Serlin , will be presenting at the 2013

- BL-8030 is a pre-clinical, second-generation NS3 protease inhibitor - - CTTQ receives development and commercialization rights in China and Hong Kong - JERUSALEM --(BUSINESS WIRE)--Jun. 10, 2013-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that

- Partial results expected in Q4 2013 – JERUSALEM --(BUSINESS WIRE)--Jun. 6, 2013-- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today enrollment of the first patient in a Phase 2 trial for BL-8040, for the treatment of acute myeloid leukemia (AML).

JERUSALEM --(BUSINESS WIRE)--May. 17, 2013-- BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a biopharmaceutical development company, announced today that it has entered into an at-the-market (ATM) sales agency agreement with Stifel. Pursuant to this agreement, the Company may from time to time, in its

JERUSALEM --(BUSINESS WIRE)--May. 9, 2013-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its Chief Financial and Operating Officer, Philip Serlin , will present at the

JERUSALEM --(BUSINESS WIRE)--May. 7, 2013-- BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a biopharmaceutical development company, today reported its results for the quarter ended March 31, 2013 . Recent Highlights: •   BL-7040 (IBD) – Received positive results from a Phase 2 proof-of-concept study to

JERUSALEM --(BUSINESS WIRE)--May. 2, 2013-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that the Company was invited to deliver an oral presentation at the 2013 National Education Conference & Gluten-Free Expo , the Celiac Disease

Management to Hold Conference Call at 10:00 A.M. EST JERUSALEM --(BUSINESS WIRE)--Apr. 30, 2013-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it will release its unaudited financial results for the quarter ended March 31, 2013 on

- Interim results are expected by the end of 2013 - JERUSALEM --(BUSINESS WIRE)--Apr. 29, 2013-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today enrollment of the first patient in a Phase I/II trial for BL-8020, an orally available, interferon-free

JERUSALEM --(BUSINESS WIRE)--Apr. 18, 2013-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its Chief Financial and Operating Officer, Philip Serlin , will be presenting at the 12 th

- BL-7040 met the primary efficacy endpoint of the study - - BL-7040 was also shown to be safe and well tolerated - JERUSALEM --(BUSINESS WIRE)--Apr. 17, 2013-- BioLineRx (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today positive Phase IIa results for BL-7040, an

Partial results expected in Q4 2013 Final results expected in H2 2014 JERUSALEM --(BUSINESS WIRE)--Apr. 10, 2013-- BioLineRx (NASDAQ:BLRX)(TASE:BLRX), a biopharmaceutical development company, announced today that it has received all necessary regulatory approvals in the US to commence a Phase IIa

Management call scheduled for Wednesday, March 20 th , at 11:00 a.m. EDT JERUSALEM --(BUSINESS WIRE)--Mar. 20, 2013-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today announced that results from a pre-planned interim analysis of the Phase II/III CLARITY trial of

- Interim results are expected by the end of 2013 - JERUSALEM --(BUSINESS WIRE)--Mar. 13, 2013-- BioLineRx (NASDAQ:BLRX)(TASE:BLRX), a biopharmaceutical development company, announced today that it has received approval from the French regulatory authorities to commence a Phase I/II trial for

Download PDF JERUSALEM--(BUSINESS WIRE)--Mar. 12, 2013-- BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a biopharmaceutical development company, today reported its results for the year ended December 31, 2012 . “BioLineRx is rapidly approaching a significant landmark in the evolution of the Company,”

Preclinical data shows that EDP-14 significantly blocks allergic responses JERUSALEM --(BUSINESS WIRE)--Feb. 28, 2013-- BioLineRx (NASDAQ: BLRX)(TASE: BLRX), a biopharmaceutical development company, announced today that following promising pre-clinical data, EDP-14, for the treatment of severe and

– Management to hold conference call at 10:00 a.m. EST– JERUSALEM --(BUSINESS WIRE)--Feb. 26, 2013-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it will release its financial results for the quarter and year ended December 31, 2012 on

JERUSALEM --(BUSINESS WIRE)--Feb. 13, 2013-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has closed its previously announced direct placement to leading healthcare investor, OrbiMed Israel Partners Limited Partnership , an affiliate

JERUSALEM --(BUSINESS WIRE)--Feb. 6, 2013-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has entered into a definitive agreement with leading healthcare investor OrbiMed Israel Partners Limited Partnership , an affiliate of OrbiMed

JERUSALEM --(BUSINESS WIRE)--Feb. 4, 2013-- BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a biopharmaceutical development company, notes that, as previously disclosed, results from the interim analysis of the Phase II/III CLARITY clinical trial of BL-1020, a first in class, orally available,

JERUSALEM --(BUSINESS WIRE)--Jan. 31, 2013-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky , Ph.D., and its Chief Financial and Operating Officer, Philip Serlin , will be presenting at the 2013 BIO

- Cognition impairment is primary endpoint of CLARITY phase II/III trial - - Dr. Savitsky: "BL-1020's interim results mark an important landmark in the development of our lead product and the Company as a whole" - JERUSALEM --(BUSINESS WIRE)--Jan. 7, 2013-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a

JERUSALEM --(BUSINESS WIRE)--Nov. 30, 2012-- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE:BLRX), a biopharmaceutical development company, today announced that its management team will be presenting at the 2012 Fifth Annual LD MICRO Conference at the Luxe Sunset Bel Air Hotel in Los Angeles .

Download PDF Jerusalem, Israel – November 14, 2012 – BioLineRx Ltd. (NASDAQ: BLRX ; TASE: BLRX), a biopharmaceutical development company, today reported its results for the third quarter ending September 30, 2012. Highlights of the Third Quarter of 2012 and Recent Developments: BL-1020

JERUSALEM --(BUSINESS WIRE)--Nov. 12, 2012-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced that it will host an Analyst & Investor Day on Tuesday, December 4, 2012 in New York City beginning at 8:00 am EST .

JERUSALEM --(BUSINESS WIRE)--Nov. 7, 2012-- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE: BLRX ), a biopharmaceutical development company, announced today that in vivo and in vitro data demonstrating the efficacy of BL-8040 in treating chronic myeloid leukemia (CML) has been accepted for presentation at

Management to hold conference call at 9:00 a.m. EST JERUSALEM --(BUSINESS WIRE)--Nov. 5, 2012-- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE: BLRX ), a biopharmaceutical development company, announced today that it will release its unaudited financial results for the quarter ended September 30, 2012 on

– Results of interim analysis expected in Q1 2013 – JERUSALEM --(BUSINESS WIRE)--Oct. 24, 2012-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it intends to conduct an interim analysis of the Phase II/III CLARITY trial of BL-1020, a first in

- Phase I/II clinical study expected to commence in Q1 2013 - JERUSALEM --(BUSINESS WIRE)--Oct. 16, 2012-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has successfully completed the pre-clinical development of BL-8020, an orally available,

–BL-1020 is currently undergoing the CLARITY Phase II/III clinical trial with results expected in H2 2013– JERUSALEM --(BUSINESS WIRE)--Oct. 9, 2012-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that a recent analysis of the results from the Phase

JERUSALEM --(BUSINESS WIRE)--Sep. 27, 2012-- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE: BLRX ), a biopharmaceutical drug development company, announced today that it has signed a purchase agreement for the sale, from time to time, of up to $15 million of its American Depositary Shares (“ADSs”) with

– Results of Phase IIb clinical trial from September 2009 now published in the Journal of Clinical Psychiatry – – BL-1020 is currently undergoing Phase II/III CLARITY clinical trial with results expected in H2 2013 – JERUSALEM --(BUSINESS WIRE)--Sep. 27, 2012-- BioLineRx (NASDAQ: BLRX) (TASE:

Untitled Document - New patent provides at least nine years of additional protection over patents previously granted - Jerusalem, Israel – September 24, 2012 – BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that a Notice of Allowance has been received

- The new safety data, as well as pre-clinical efficacy results, presented at the Better Life for Coeliacs 2012 Conference -   Jerusalem, Israel – September 10, 2012 – BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that BL-7010, an orally available

- Phase II clinical trials are expected to commence in H1 2013 -   Jerusalem, Israel, September 4, 2012 --- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE: BLRX ), a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine

Jerusalem, Israel, August 2, 2012 --- BioLineRx Ltd. (NASDAQ: BLRX ) (TASE: BLRX ), a biopharmaceutical development company, announced today that it will release its unaudited financial results for the three-months ended June 30, 2012 on Wednesday, August 15, 2012, before the U.S. markets open.

Jerusalem, July 9, 2012 - BioLineRx (NASDAQ:BLRX; TASE:BLRX), a biopharmaceutical development company, announced today that it has received from the European Patent Office a notice of intention to grant a European patent claiming the salt of BL-1020, a first-in-class orally available treatment for

For Hebrew convenience translatioin, please click below Hebrew version Jerusalem, Israel – June 13, 2012 – BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that research underlying its EDP 10 project for the treatment of type 1 diabetes won the Hebrew

For Hebrew convenience translation, please click link below: Hebrew version Jerusalem, Israel - June 5, 2012 - BioLineRx (NASDAQ:BLRX; TASE:BLRX), a biopharmaceutical development company, announced today that two Notices of Allowance have been issued by the United States Patent and Trademark Office

For Hebrew convenience translation please click link below Hebrew version Jerusalem, May 15, 2012 --BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today reported its results for the quarter ended March 31, 2012. Highlights for the First Quarter of 2012:

For Hebrew convenience translation, please click link below: Hebrew version Jerusalem, Israel, May 8, 2012 --- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it will release its unaudited financial results for the three-months ended March

For Hebrew convenience translation please click on link below: Hebrew version Jerusalem, Israel – April 25, 2012 - BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that an Issue Notification has been received from the United States Patent and Trademark

JERUSALEM, April 23, 2012 -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX.TA), a biopharmaceutical development company, announced the release today of its investor relations app for iPhone, now available for free at the Apple App store on the iPhone or at http://bit.ly/I6oKhw .

JERUSALEM, March 28, 2012 -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX.TA), a biopharmaceutical development company, today announced that its Chief Financial and Operating Officer, Philip Serlin, and its Vice President of Research and Development, Leah Klapper, Ph.D., will be presenting at the 2012

Jerusalem , March 22, 2012 - BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today reported its results for the fourth quarter and year ended December 31, 2011. Kinneret Savitsky, Ph.D., CEO of BioLineRx, remarked, “2011 was a very significant year for BioLineRx

For Hebrew convenience translation please click on the link below Hebrew version Jerusalem, March 7, 2012 - BioLineRx (NASDAQ:BLRX; TASE:BLRX), a biopharmaceutical development company, announced today that a European patent has been granted claiming BL-1020's composition and its use for the

JERUSALEM, March 7, 2012 -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, today announced that its Chief Executive Officer, Kinneret Savitsky, and its Vice President of Business Development, David Malek, will be presenting at the 2012 Annual Roth Growth

BioLineRx Receives Approval for Commencing Phase II Clinical Trial of BL-7040, an Orally Available Treatment for Inflammatory Bowel Disease For Hebrew convenience translation please click link below Hebrew version Jerusalem, March 5, 2012 - BioLineRx (NASDAQ:BLRX; TASE:BLRX) a biopharmaceutical

For Hebrew conveneience translation please click link below: Hebrew version Jerusalem, Israel - February 29, 2012 - BioLineRx (NASDAQ:BLRX; TASE:BLRX), a biopharmaceutical development company, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark

JERUSALEM, February 28, 2012 -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX), announced today that it has closed its previously announced $15 million private placement to healthcare-focused U.S. institutional investors. As a result, the Company sold approximately 5.25 million American Depositary Shares

For Hebrew convenience translation please click below Hebrew Version Jerusalem, Israel – February 21, 2012 – BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for

For Hebrew convenience translation please click link below: Hebrew Version Jerusalem, Israel - February 16, 2012 – BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) (the "Company”), a biopharmaceutical development company, announced today it has entered into definitive agreements with healthcare-focused

Jerusalem, Israel, February 7, 2012 - BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 2012 BIO CEO &

For Hebrew convenience translation please press link below Hebrew version   Jerusalem, Israel – February 6, 2012 – BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to

For Hebrew convenience translation please click on link Hebrew Translation Jerusalem, Israel – January 24, 2012 – BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience, a French company

For Hebrew convenience translation please click link below : Hebrew version Jerusalem, January 3, 2011 - BioLineRx (NASDAQ:BLRX; TASE:BLRX), a biopharmaceutical development company, announced today the commencement of the PRESERVATION I clinical trial, a CE Mark registration trial of BCM (BL-1040),

For Hebrew convenience translation please click link below: Hebrew Version Jerusalem and Tel Aviv, Israel - December 13, 2011 – BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, and Compugen Ltd. (NASDAQ: CGEN), a drug discovery company, announced today that they have

For Hebrew convenience translation please click link below: Hebrew version Jerusalem, December 6, 2011 - BioLineRx (NASDAQ:BLRX) (TASE:BLRX) announced today the final results of the Phase Ia study of BL-1021, an orally available small molecule for neuropathic pain.

For Hebrew convenience translation please click on the link below Hebrew Version Jerusalem, November 22, 2011 - BioLineRx (NASDAQ:BLRX; TASE:BLRX), a biopharmaceutical development company, announced today that it has received approval from the Indian regulatory authorities and the Indian local

For Hebrew version please click below: Hebrew version Jerusalem, Israel, Sep. 27, 2011 – BioLineRx (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, today announced that data from the successfully completed Phase IIb EAGLE  study of BL-1020, a first in class GABA-enhanced

Jerusalem, September 16, 2011 - BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today announced that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 2011 UBS Global Life

For Hebrew version please click link below Hebrew Version Jerusalem , Israel, September 15, 2011 - BioLineRx (NASDAQ: BLRX) (TASE: BLRX),  a biopharmaceutical development company, announced today that BL-5010, for the non-surgical removal of benign skin lesions, has received European confirmation

For Hebrew version please click on the link below: Hebrew Version Jerusalem, September 13, 2011 - BioLineRx (NASDAQ: BLRX) (TASE: BLRX) announced today the last visit of the last subject and preliminary results of the Phase Ia study of BL-1021, an orally available small molecule for neuropathic

Jerusalem, September 8, 2011 – BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today announced that its Chief Executive Officer, Kinneret Savitsky, and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 2011 Rodman and Renshaw

For Hebrew version please click on the link below: Hebrew Version Jerusalem, September 7, 2011 - BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the

Jerusalem , August 23, 2011 - BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today reported its results for the second quarter ending June 30, 2011. “During the second quarter we continued developing, advancing and enriching our pipeline, while focusing on

Jerusalem, July 25, 2011 - BioLineRx (TASE: BLRX) (NASDAQ: BLRX), a biopharmaceutical development company, today announced that it has listed and begun trading American Depositary Receipts (ADRs) through BNY Mellon. Each BioLineRx ADR represents 10 ordinary shares and trades on the NASDAQ Capital

Jerusalem, July 5, 2011 - BioLineRx (TASE:BLRX), a biopharmaceutical drug development company, today announced that it plans to list its shares through American Depositary Receipts (ADRs), to be traded on the NASDAQ under ticker "BLRX.” The Bank of New York Mellon has been appointed as the

Jerusalem, July 5, 2011 - BioLineRx (TASE:BLRX) announced today the enrollment of the first subject in a Phase I study of BL-1021, an orally available small molecule for treating neuropathic pain. This clinical trial will be a first-in-human, single-site, double-blind, placebo controlled study to

Jerusalem, June 28, 2011 - BioLineRx (TASE:BLRX), a biopharmaceutical development company, announced today the enrollment of the first patient in the Phase II/III CLARITY clinical trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.

Jerusalem, June 27, 2011 - BioLineRx (TASE:BLRX), a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for

Jerusalem, May 17, 2011 . BioLineRx (TASE:BLRX) announced today that it has acquired the rights to compound BL-7030, a novel molecule for targeted cancer therapy, from Algen, which received exclusive rights from Yissum, the Hebrew University of Jerusalem.  BL-7030 is a vector targeted to epidermal

Jerusalem, Israel, May 11, 2011 – BioLineRx Ltd. (TASE: BLRX), a biopharmaceutical development company dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies, announced today the signing of an agreement with Cypress Bioscience

Jerusalem, April 4, 2011 . BioLineRx (TASE:BLRX) announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application covering the BL-1020 drug and its use for the treatment of schizophrenia.

Jerusalem, March 28, 2011 . BioLineRx (TASE: BLRX) announces its financial results for 2010. • 2010 revenue increased to NIS 113.2 million from NIS 63.9 million in 2009 • Cash and short term investments at December 31 2010 were NIS 139.8 million Dr. Kinneret Savitsky, BioLine's CEO , stated, "We

BioLineRx (TASE:BLRX) announced today that the first pivotal trial for BL-1040*, a novel medical device intended for patients following acute myocardial infarction (AMI), is anticipated to commence in the second half of 2011. Ikaria Inc., which acquired the license for continuation of development

Jerusalem, January 23, 2011 . BioLineRx (TASE:BLRX) today announced that it has been advised by Royalty Pharma, the new parent company of Cypress Bioscience Inc., that it is committed to enhance the value of Cypress’ pipeline assets, which include BioLineRx’s BL-1020 (CYP-1020) compound, a novel

Jerusalem, January 4, 2011 . BioLineRx (TASE:BLRX) announces that the Office of the Chief Scientist at the Israeli Ministry of Industry, Trade and Labor (OCS) has renewed BioLineRx's franchise for the biotechnology incubator, BioLine Innovations Jerusalem (BIJ), for an additional two years.

Jerusalem, December 28, 2010. BioLineRx (TASE:BLRX) announces receipt of positive results from the Phase I/II clinical trial of BL-5010, a novel formulation for the non-surgical removal of skin lesions.   The recently completed open-label, single-arm trial was conducted in 60 patients with

Opening bell ceremony at NASDAQ with participants from NASDAQ-TASE Biomed Investors Conference. VP Business Development of BioLineRx, Nir Gamliel, is  fourth on the right.

Jerusalem, Israel, November 29, 2010 . BioLineRx (BLRX: TASE) is pleased to announce that it will participate in an investor conference highlighting the life-sciences industry on December 6, 2010, co-sponsored by NASDAQ and the Tel-Aviv Stock Exchange (TASE).

Jerusalem, November 24, 2010 - BioLineRx (BLRX:TASE) reports its operating results for the quarter and nine months ended September 30, 2010. Highlights: • Revenues in Q3 amounted to NIS 113 million, resulting from the commercialization of BL-1020 to Cypress Bioscience Inc.

Jerusalem, Israel, October 27, 2010 . BioLineRx is pleased to announce receipt of a distinguished poster award for the clinical trial of BL-1020, a novel molecule for the treatment of schizophrenia, at the 6th International Society for CNS Clinical Trials and Methodology (ISCTM) Conference,

Jerusalem, Israel, August 30, 2010 . BioLineRx is pleased to announce that data on BL-1021, a new chemical entity (NCE) for treatment of neuropathic pain, will be presented at 13th World Congress on Pain, Montreal Canada. This Congress is the biennial meeting of the International Association for

EDP-01, an innovative compound for treating type II diabetes, has successfully completed BioLineRx's Early Development Program (EDP) and will enter the Company's main product pipeline. This is a significant milestone for BioLineRx, as EDP-01 is the first graduate of the EDP program to enter its

Jerusalem, 11 August, 2010 - BioLineRx (TASE: BLRX) is pleased to announce that it has received approval from the Israeli Office of the Chief Scientist of the Ministry of Industry, Trade and Labor (“OCS”) for the out-licensing agreement with Cypress Bioscience, Inc. (NASDAQ: CYPB).

Jerusalem, July 11, 2010 .  The Company hereby announces that, on July 11, 2010, the Company’s Board of Directors formally approved the process of registration with the U.S. Securities and Exchange Commission of an offering of the Company’s shares and a simultaneous listing of its securities on the

Jerusalem, 20 June, 2010 - BioLineRx (TASE: BLRX) has signed an out-licensing agreement for BL-1020, a novel drug for schizophrenia, with Cypress Bioscience, Inc., a US-based pharmaceutical company (NASDAQ: CYPB). Closing of the transaction is subject to the approval of the Israeli Office of the

The Israel Laboratory Accreditation Authority (ISRAC) has granted BioLineRx's analytical laboratories Good Laboratory Practices (GLP)  accreditation as of  March 4, 2010 . From this date, BioLineRx's analytical laboratories have been added to the ISRAC test facilities list and are officially

BioLineRx Ltd . (the "Company") is pleased to announce that Ikaria Holdings Inc. has made a $10 million milestone payment, according to the terms of the licensing agreement between the parties, following successful completion of the phase I/II clinical trial assessing the safety and feasibility of

On Thursday April 15,  Yona Geffen, PhD, from BioLineRX will be presenting "A double-blind placebo control study evaluating the efficacy and safety of BL-1020 , a GABA enhanced antipsychotic for the treatment of schizophrenia" at  the SIRS Conference, "Cognition in Schizophrenia" Session.

BioLineRx Ltd. (“the Company”) is pleased to announce that on March 4, 2010, it received the final assessment of the ISMB regarding the Phase I/II clinical trial for BL-1040, a medical device indicated for the treatment of patients who have experienced a heart attack.

Jerusalem, Israel, January 17th, 2010: Following our previous press releases (published September 14th and 23rd, 2009) announcing that BL-1020 has successfully met its primary and secondary efficacy endpoints, as well as significantly improved cognition in the 6-week phase 2b EAGLE (Effective

Jerusalem, Israel, October 15, 2009 - BioLineRx Ltd. (TASE: BLRX), a clinical stage drug development company, today announced that its Early Development Program (EDP) has been awarded a prestigious R&D grant from the Canada-Israel Research & Development Foundation (CIIRDF).

Jerusalem, Israel: Following our previous press release (published September 14th, 2009) announcing that BL-1020 has successfully met its primary and secondary efficacy endpoints from the phase 2b EAGLE (Effective Anti-psychosis via GABA Level Enhancement) trial, we are pleased to report positive

BL-1020 meets primary and secondary efficacy endpoints from the phase 2b EAGLE trial Jerusalem, Israel, September 14th, 2009- BioLineRx announced today top line results from its phase 2b EAGLE (Effective Antipsychosis via GABA Level Enhancement) study assessing the efficacy, safety and tolerability

Clinton, NJ and Jerusalem, Israel, July 6, 2009 – Ikaria Holdings, Inc. and BioLineRx Ltd. (TASE: BLRX) today announced that Ikaria has entered into an agreement to obtain a worldwide exclusive license to BioLineRx’s BL-1040, a potential breakthrough treatment for preventing pathological cardiac

BioLineRx’s CEO Dr. Morris Laster: “These results are extremely important for the confirmation of the mode of action of BL-1020 in reducing EPS and improving cognition” Jerusalem, Israel, June 21st, 2009- BioLineRx, a drug development company with products in advanced clinical and pre-clinical

BioLineRx’s CEO Dr. Morris Laster: “BL-5010 is an exciting product in development that may offer a fast, safe and painless way to eliminate skin lesions.” BioLineRx, a drug development company with products in advanced clinical and pre-clinical testing, today announced the initiation of a Phase

• Fifteen Patients Successfully Treated With BL-1040 With No Complications; • Five Patients Completed Six Months Follow up Period with prevention of LV remodeling Jerusalem, ISRAEL, June, 2009 - BioLineRx Ltd. (TASE: BLRX), a clinical stage drug development company, today announced positive

BioLineRx Ltd. (TASE: BLRX) announced that data from preclinical behavioral models of BL-1020, a GABA-enhanced antipsychotic for the treatment of schizophrenia, will be presented today at the Society of Biological Psychiatry (SOBP) 64rd Annual Scientific Convention & Meeting held in Vancouver,

BioLineRx completed the enrolment of 360 schizophrenia patients for BL-1020 phase IIb trial. The company completed the recruitment phase two months ahead of schedule. BioLineRx started the phase IIb trial, aimed at evaluating the efficacy, tolerability and safety of BL-1020 in July 2008.

Five out of 30 patients already safely treated. Final results of trial expected in Q3 2009 Jerusalem, ISRAEL, January 12, 2009 - BioLineRx Ltd. (TASE: BLRX), a clinical stage drug development company, today announced that the Independent Safety Monitoring Board (ISMB) for the BL-1040 pilot study

Jerusalem, Israel, November 12, 2008 – Yissum Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, and BioLineRx Ltd. (TASE: BLRX), a clinical stage drug development company, today announced that they have signed a worldwide exclusive license agreement for BioLineRx to

Jerusalem, Israel, July 16, 2008 – BioLineRx Ltd. (TASE: BLRX), a clinical stage drug development company, announced today that BL-1040, a novel myocardial implant for the treatment of acute myocardial infarction (MI), has been selected as one of the Top 10 most promising cardiovascular projects in